American Society of Hirudotherapy

Direct Thrombin Inhibitors

From leech hirudin to modern pharmaceuticals — the complete DTI drug class

Last Updated: May 27, 2026ASH Editorial · based on the booksTier A — FDA-cleared use contextGRADE: High
FDA-approved pharmaceutical (drug context): FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Drug pharmacology reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Drug-vs-leech distinction

FDA-approved drug: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.

Direct Thrombin Inhibitors (DTI class)

Approval:
FDA-approved drug class: bivalirudin, dabigatran, argatroban, lepirudin, desirudin
Indication:
PCI anticoagulation, HIT, AFib stroke prevention, VTE prevention/treatment
Derived from:
Hirudin lineage (bivalirudin, lepirudin, desirudin) from Hirudo medicinalis salivary glands; dabigatran and argatroban are synthetic thrombin inhibitors that share hirudin's target but are not derived from the leech
FDA-cleared medical device: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.

Hirudo medicinalis

FDA status:
FDA-cleared medical device (K040187, June 2004)
Cleared indication:
Venous congestion in surgical flaps and replanted tissue

These are two distinct regulatory contexts. The drug above is a recombinant or synthetic pharmaceutical analog regulated under FDA NDA/BLA pathways. The whole-leech therapy is regulated as a medical device. Clinical claims for the drug do NOT extend to whole-leech therapy, and vice versa.

Translational Success Story

Direct thrombin inhibitors are FDA-approved pharmaceutical drugs, not medicinal leech therapy. This page documents how leech hirudin led to the recombinant hirudins and bivalirudin; other direct thrombin inhibitors, such as argatroban and dabigatran, were designed independently of hirudin.

GRADE Evidence Level: High

Consistent results from well-designed RCTs or overwhelming observational evidence

Direct thrombin inhibitors (DTIs) include the only approved drugs derived from medicinal leech biology. Hirudin, isolated from Hirudo medicinalis, led to the recombinant hirudins lepirudin (FDA 1998) and desirudin (2003) and to the synthetic peptide bivalirudin (2000). Other DTIs were built by synthetic chemistry without hirudin as a template: argatroban (2000), derived from arginine, and dabigatran (2010), designed from the benzamidine inhibitor NAPAP — the first oral DTI approved by the FDA.

The DTI Drug Family

DrugSourceTypeAffinityRouteStatus
Hirudin (native)H. medicinalis salivaBivalent, irreversible~20 fMN/A (research)Not a drug — biological precursor
Lepirudin (Refludan)Recombinant hirudinBivalent, irreversible~20 fMIVFDA-approved 1998; withdrawn 2012
Desirudin (Iprivask)Recombinant hirudin variantBivalent, irreversible~20 fMSCFDA-approved 2003; discontinued in the US
Bivalirudin (Angiomax)Synthetic hirudin fragmentBivalent, reversible~2 nM (Ki)IVFDA-approved 2000; Class I ACC/AHA
ArgatrobanSynthetic (L-arginine derivative)Univalent, reversible~39 nMIVFDA-approved 2000
Dabigatran (Pradaxa)Synthetic (hirudin-inspired)Univalent, reversible~4.5 nMOralFDA-approved 2010; generic versions FDA-approved from 2020

Translational Timeline

1884

Haycraft discovers leech SGS prevents blood coagulation

1957

Markwardt isolates hirudin from Hirudo medicinalis

1976

Full amino acid sequence of hirudin determined (65 residues)

1990

Crystal structure of hirudin-thrombin complex solved — reveals bivalent binding

1997

Bivalirudin (synthetic 20-AA hirudin fragment) enters clinical trials

1998

Lepirudin (recombinant hirudin) FDA-approved — first DTI

2000

Bivalirudin and argatroban FDA-approved

2008

HORIZONS-AMI: bivalirudin demonstrates lower 30-day cardiac mortality (1.8% vs 2.9%) in STEMI PCI

2010

Dabigatran FDA-approved — the first oral DTI approved by the FDA, a synthetic molecule designed from the inhibitor NAPAP (not derived from hirudin)

2015

Idarucizumab approved as dabigatran reversal agent

2025

Bivalirudin retains Class I, Level B-R ACC/AHA recommendation for STEMI PCI (JACC 2025)

2026

Pradaxa (dabigatran) patent expires March 7, 2026 — generics available

Mechanism: How DTIs Work

Bivalent DTIs

Bind both the active site and exosite 1 (fibrinogen recognition site) of thrombin simultaneously. Native hirudin binds with femtomolar affinity (Kd ~20 fM) — the tightest protein-protein interaction measured in nature. Bivalirudin uses the same dual-binding but is reversible, conferring a superior safety profile.

Univalent DTIs

Bind only the active site of thrombin. Argatroban (IV, hepatic clearance) and dabigatran (oral, renal clearance) are both univalent. Despite lower individual affinity, they achieve therapeutic anticoagulation through concentration-dependent inhibition. Dabigatran was designed from the X-ray structure of thrombin bound to the synthetic inhibitor NAPAP.

Advantages Over Heparin

  • Clot-bound thrombin: DTIs inhibit both free and fibrin-bound thrombin; heparin cannot reach clot-bound thrombin
  • No HIT risk: DTIs do not interact with platelet factor 4; used as HIT treatment
  • Predictable PK: No antithrombin III dependence; linear dose-response
  • No natural inhibitors: Unlike heparin, DTIs are not neutralized by platelet factor 4 released during thrombosis

Key Drugs: Summary

Bivalirudin

$636M

Peak annual revenue

  • Class I for STEMI PCI (2025 ACC/AHA)
  • 43% lower 1-year cardiac mortality, 2.1% vs 3.8% (HR 0.57; HORIZONS-AMI, Mehran 2009)
  • Reversible, 25-min half-life
  • Generic available

Dabigatran

~€1.5B (2018)

Peak annual revenue

  • First oral DTI (FDA 2010)
  • RE-LY: superior stroke prevention vs warfarin
  • Reversal agent: idarucizumab
  • Patent expired March 2026; generics available

Argatroban

HIT

Primary indication

  • First-line for HIT treatment
  • Hepatically cleared (safe in renal failure)
  • Continuous IV infusion
  • Not hirudin-derived (L-arginine based)

Lepirudin: A Cautionary Tale

Withdrawn 2012

Lepirudin (Refludan), the first recombinant hirudin, was FDA-approved in 1998 for HIT treatment. It was withdrawn in 2012 by its manufacturer for commercial reasons. Immunogenicity was a documented limitation: anti-hirudin antibodies were reported in up to 74% of patients treated with r-hirudin for more than 5 days, and fatal anaphylaxis occurred in 4 of about 2,500 re-exposed patients (about 0.16%; about 0.015% on first exposure). Bivalirudin, designed in 1990, is a shorter, synthetic, reversible peptide.

Market Impact

Bivalirudin, the leech-derived member of the class, reached peak worldwide sales of $636 million in 2014, before U.S. generics arrived in 2015. Dabigatran, a synthetic DTI not derived from the leech, became a blockbuster: Boehringer Ingelheim reported Pradaxa net sales of about €1.5 billion in 2018, and generic dabigatran capsules are now marketed in the U.S.

Studies in the ASH clinical-study library

Entries from our clinical-study library filed under this topic. Each entry states its own study design and GRADE rating.

All studies in the library

Related Resources

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.